Unknown

Dataset Information

0

Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer.


ABSTRACT: Immunotherapy benefits selected cases of gastric cancer (GC), but the correlation between biomarkers and prognosis is still unclear. Fifty-two patients with GC who underwent immunotherapy were enrolled from June 2016 to December 2020. Their clinical features and biomarkers-microsatellite instability-high (MSI-H), programmed cell death ligand 1 (PD-L1) combined positive score (CPS), and Epstein-Barr encoding region (EBER)-were analyzed. Eight patients had MSI-H, five patients had EBER, 29 patients had CPS ≥ 1, and 20 patients had no biomarker. The overall response rates (ORRs) of the MSI-H, EBER, PD-L1 CPS ≥ 1, and all-negative group were 75%, 60%, 44.8%, and 15%, respectively. Compared with that of the all-negative group, progression-free survival (PFS) was better in the MSI-H (p = 0.018), CPS ≥ 5 (p = 0.012), and CPS ≥ 10 (p = 0.006) groups, but not in the EBER (p = 0.2) and CPS ≥ 1 groups (p = 0.35). Ten patients had combined biomarkers, CPS ≥ 1 with either MSI-H or EBER. The ORRs were 66.7% for CPS ≥ 1 and MSI-H and 75% for CPS ≥ 1 and EBER. PFS was better in patients with combined biomarkers (p = 0.01). MSI-H, EBER, and CPS are useful biomarkers for predicting the efficacy of immunotherapy.

SUBMITTER: Yu HY 

PROVIDER: S-EPMC8750088 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8216206 | biostudies-literature
| S-EPMC5429283 | biostudies-literature
| S-EPMC7271517 | biostudies-literature
| S-EPMC2865194 | biostudies-literature
| S-EPMC3903497 | biostudies-literature
| S-EPMC9113025 | biostudies-literature
| S-EPMC8460994 | biostudies-literature
| S-EPMC8185367 | biostudies-literature
| S-EPMC6073163 | biostudies-literature
| S-EPMC6817827 | biostudies-other